Related Experiment Video
Updated: Jun 22, 2026
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered
Cecilia Folio1, María I Mora, Marta Zalacain
1Department of Pediatrics, University Clinic of Navarra, Pamplona, Spain.
Abstract:
With a view to identify the proteins involved in transformation, metastasis or chemoresistance in pediatric osteosarcoma, we carried out a new experimental approach based on comparison of the proteomic profile of paired samples of osteosarcoma and normal bone tissues from the same patient. The proteomic profiles of five pairs of cell lines (normal vs tumoral) were obtained by two-dimensional difference gel electrophoresis. We detected 56 differential protein spots (t test, p < 0.05). Subsequent protein characterization by nano-LC-ESI-MS/MS enabled us to identify some of these proteins, 16 of which were chosen on the basis of the change of their relative abundance between osteosarcomas and paired normal bones and also because their involvement was supported by the genomic analysis. Two of the 16 proteins, Alpha-crystallin B chain (CRYAB) and ezrin (EZR1), were selected for further studies: an immunohistochemical analysis of a TMA (tissue microarray) and real-time PCR for a set of 14 osteosarcoma/normal-bone pairs. The results of this second tier of studies confirmed that there were significant increases in the amounts of CRYAB and ezrin, especially in advanced stages of the disease. Our overall conclusion is that proteomic profiling of paired samples of osteosarcoma and normal bone tissues from the same patient is a practicable and potentially powerful way of initiating and proceeding with a search for proteins and genes involved in pediatric osteosarcoma.
Insights
Proteomic profiling of pediatric osteosarcoma identified increased levels of Alpha-crystallin B chain (CRYAB) and ezrin (EZR1) in tumor tissues. These proteins may play a role in osteosarcoma progression and could be targets for future therapies.
Area of Science:
- Oncology
- Proteomics
- Molecular Biology
Background:
- Pediatric osteosarcoma is a challenging bone cancer.
- Identifying key proteins in tumor progression is crucial for developing targeted therapies.
Purpose of the Study:
- To identify proteins involved in pediatric osteosarcoma transformation, metastasis, and chemoresistance.
- To compare proteomic profiles of paired osteosarcoma and normal bone tissues.
Main Methods:
- Two-dimensional difference gel electrophoresis (2D-DIGE) to analyze protein expression.
- Nano-liquid chromatography-electrospray ionization-tandem mass spectrometry (nano-LC-ESI-MS/MS) for protein identification.
- Immunohistochemical analysis and real-time PCR to validate protein expression levels.
Main Results:
- 56 differential protein spots were detected between tumor and normal tissues.
- Alpha-crystallin B chain (CRYAB) and ezrin (EZR1) showed significantly increased abundance in osteosarcomas.
- Elevated CRYAB and EZR1 levels correlated with advanced disease stages.
Conclusions:
- Proteomic profiling of paired patient samples is an effective strategy for identifying disease-associated proteins.
- CRYAB and EZR1 are potential biomarkers and therapeutic targets in pediatric osteosarcoma.
